Evolus (EOLS) EBITDA (2017 - 2026)

Evolus has reported EBITDA for 10 years, with the latest figure at -$10.8 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 42.65% year-over-year to -$10.8 million; the trailing twelve-month figure through Mar 2026 stood at -$42.9 million (up 24.12% YoY), and the FY2025 full-year result was -$50.9 million, changed 0.01% from the prior year.
• EBITDA for Q1 2026 stood at -$10.8 million, down from $111000.0 in the prior quarter.
• The five-year high for EBITDA was $111000.0 in Q4 2025, with the low at -$23.5 million in Q2 2022.
• Historically, EBITDA has averaged -$14.7 million across 5 years, with a median of -$15.3 million in 2025.
• Annual changes were most pronounced in 2022 — EBITDA tumbled 375.02% — and 2025, when it jumped 101.58%.
• Evolus' EBITDA stood at -$13.1 million in 2022, then gained by 11.28% to -$11.7 million in 2023, then soared by 39.86% to -$7.0 million in 2024, then jumped by 101.58% to $111000.0 in 2025, then plunged by 9826.13% to -$10.8 million in 2026.
• The last three EBITDA figures came in at -$10.8 million (Q1 2026), $111000.0 (Q4 2025), and -$15.3 million (Q3 2025), per Business Quant data.